3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
2
Smoldering Multiple Myeloma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myeloid, Acute
1
Carcinoma, Squamous Cell
1
Interventions
Lenalidomide
3
daratumumab
2
Dexamethasone
2
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
Watchful Waiting
1
Stem Cell Transplantation
1
Peripheral Blood Stem Cell Transplantation
1
Observation
1
Melphalan
1
Maintenance
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Smoldering Multiple Myeloma
×
Maintenance
×
Clear all
NCT00480363
2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3
Completed
120 enrolled